title: Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy.
abstract: BACKGROUND
  Parkinson's disease (PD) is a chronic neurodegenerative disease which at present has no cure, and it usually results in severe disability. The burden of PD increases as the illness progresses, resulting in the extensive utilisation of both health and community services. Knowledge of healthcare use patterns and of their determinants may greatly contribute to improve patient care, however few studies have examined this issue in PD. The present study was devised to describe the type of and reasons for medical healthcare resource use in persons with PD attending a Centre for PD and Movement Disorders, and to examine drug prescriptions issued on such occasions.
  
  
  METHODS
  The study was a retrospective, cross-sectional survey in a cohort of ambulatory patients with PD, conducted by means of standard interviews.
  
  
  RESULTS
  In the year before the study, 92 (70.8%) of 130 patients used medical healthcare resources: 1/5 of the patients was admitted to hospital, 1/5 to emergency room, 2/5 were visited by a non-neurology specialist, and 1/4 by the GP. Reasons were: nearly 20% programmed hospital admissions and visits, and more than 25% injuries and musculo-skeletal diseases. Other conditions typically occurring in PD (e.g. dementia, diabetes and cardio- and cerebro-vascular disease) were less frequently involved. On such occasions, drugs for PD were occasionally changed, however drug prescriptions for other indications were issued to more than 66% of the patients.
  
  
  CONCLUSIONS
  Several physicians other than the neurologist may take care of PD patients on different occasions, thus emphasising the need for communication between the reference neurologist and other physicians who from time to time may visit the patient.
authors.affiliation: Department of Clinical Medicine, Section of Experimental and Clinical Pharmacology, University of Insubria, Varese, Italy. marco.cosentino@uninsubria.it
authors.forename: Marco
authors.initials: M
authors.lastname: Cosentino
authors.forename: Emilia
authors.initials: E
authors.lastname: Martignoni
authors.forename: Donatella
authors.initials: D
authors.lastname: Michielotto
authors.forename: Daniela
authors.initials: D
authors.lastname: Calandrella
authors.forename: Giulio
authors.initials: G
authors.lastname: Riboldazzi
authors.forename: Claudio
authors.initials: C
authors.lastname: Pacchetti
authors.forename: Gianmario
authors.initials: G
authors.lastname: Frigo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Nappi
authors.forename: Sergio
authors.initials: S
authors.lastname: Lecchini
mesh_terms: D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D015897:Comorbidity; D003430:Cross-Sectional Studies; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004599:Electric Stimulation Therapy; D005260:Female; D006296:Health Services / Q000706:statistics & numerical data*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007558:Italy; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009462:Neurology; D009819:Office Visits / Q000706:statistics & numerical data; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D010348:Patient Care Team; D014600:Utilization Review
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa